Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 15,155 $ 9,589
Marketable securities, current 12,955 39,091
Collaboration receivable 400 1,891
Prepaid expenses and other current assets 1,022 2,599
Total current assets 29,532 53,170
Property and equipment, net 159 333
Other assets 0 166
Total assets 29,691 53,669
Current liabilities:    
Accounts payable 699 725
Accrued clinical and development expenses 1,908 6,834
Accrued liabilities 1,112 3,269
Total current liabilities 3,719 10,828
Warrant liability 2,988 1,864
Deferred rent 63 131
Total liabilities 6,770 12,823
Commitments and contingencies (Note 7) 0 0
Stockholders’ equity:    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 71,560,294 shares at September 30, 2016 and 71,462,059 shares at December 31, 2015 72 71
Additional paid-in capital 372,699 370,236
Accumulated other comprehensive loss 2 (21)
Accumulated deficit (349,852) (329,440)
Total stockholders’ equity 22,921 40,846
Total liabilities and stockholders’ equity $ 29,691 $ 53,669